PDF(Sci-hub)
Abstract：
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD). Individualized treatment regimens aim at obtaining the same visual benefits of monthly injections with a reduced number of injections and follow-up visits, and, consequently, of treatment burden. The target of these strategies is to timely recognize lesion recurrence, even before visual deterioration. Early detection of lesion activity is critical to ensure that clinical outcomes are not compromised by inappropriate delays in treatment, but questions remain on how to effectively monitor the choroidal neovascularization (CNV) activity. To assess the persistence/recurrence of lesion activity in patients undergoing treatment for nAMD, an expert panel developed a decision algorithm based on the morphological features of CNV. After evaluating all current retinal imaging techniques, the panel identified optical coherent tomography as the most reliable tool to ascertain lesion activity when funduscopy is not obvious.
摘要：
玻璃体内注射抗血管内皮生长因子药物代表了新生血管性年龄相关性黄斑变性（nAMD）的现行标准。个体化治疗方案旨在获得与每月注射相同的视觉益处，减少注射次数和随访次数，and,因此,治疗负担。这些策略的目标是及时识别病变复发，甚至在视力恶化之前。早期发现病变活动对于确保临床结果不因治疗不当延迟而受到影响至关重要。但如何有效监测脉络膜新生血管(CNV)活性仍存在疑问.为了评估接受nAMD治疗的患者病灶活动的持续性/复发，专家小组开发了一种基于CNV形态特征的决策算法。在评估了目前所有的视网膜成像技术后，小组认为,当眼底镜检查不明显时,光学相干断层扫描是确定病变活动的最可靠工具.
